Author

E. A. Egusa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. P. Bidkar· 1 shared A. Wadhwa· 1 shared B. Liu· 1 shared D. Beckford-Vera· 1 shared D. M. Wilson· 1 shared E. Chan· 1 shared H. F. VanBrocklin· 1 shared J. Chou· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. P. Bidkar

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy

A. P. Bidkar, S. Wang, K. N. Bobba, E. Chan, S. Bidlingmaier, E. A. Egusa, R. Peter, U. Ali, N. Meher, A. Wadhwa, S. Dhrona, D. Beckford-Vera, Y. Su, R. Tang, L. Zhang, , R. R. Flavell

This study develops and evaluates [225Ac]DOTA-YS5, a radioimmunotherapy for prostate cancer, showing high efficacy in xenograft models but nephrotoxicity at higher doses.

bioRxiv · Oct 13, 2022 · PreprintCancer Biology